AlloVir (NASDAQ:ALVR) Shares Up 1%

AlloVir, Inc. (NASDAQ:ALVR)’s share price rose 1% during trading on Monday . The company traded as high as $0.78 and last traded at $0.76. 42,495 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 688,295 shares. The stock had previously closed at $0.75.

AlloVir Stock Performance

The firm has a market cap of $87.40 million, a PE ratio of -0.46 and a beta of 0.78. The stock has a 50-day simple moving average of $0.76 and a two-hundred day simple moving average of $0.76.

AlloVir (NASDAQ:ALVR) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. As a group, sell-side analysts anticipate that AlloVir, Inc. will post -0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On AlloVir

Several large investors have recently added to or reduced their stakes in ALVR. Cubist Systematic Strategies LLC boosted its position in AlloVir by 152.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after buying an additional 30,072 shares during the period. Twin Focus Capital Partners LLC acquired a new stake in AlloVir in the fourth quarter valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of AlloVir during the 2nd quarter valued at $55,000. Price T Rowe Associates Inc. MD grew its stake in shares of AlloVir by 127.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after acquiring an additional 54,900 shares during the last quarter. Finally, Marquette Asset Management LLC purchased a new stake in AlloVir during the 1st quarter worth approximately $135,000. 66.05% of the stock is owned by institutional investors.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.